J&J Sets The Pace In Race To $10bn RSV Vaccine Market
80% Efficacy Against Severe Disease In 65+ Group
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.
You may also be interested in...
The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.
Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.